Cancer is driven by numerous genetic and epigenetic changes occurring at the cellular level.These changes drive normal cells to proliferate and escape processes thatusually regulate their survival and migration. Many of these alterations areoften associated with signaling pathways which regulate cell growth anddivision, cell death, survival, invasion and metastasis, and angiogenesis.Almost all cancer cells show high expression of signaling components includinggrowth factor receptor tyrosine kinases (RTKs), small GTPases, serine/threoninekinases, cytoplasmic tyrosine kinases, lipid kinases, estrogen receptor,activation of transcription factors Myc and NF-κB, etc. Updated knowledge aboutthese signaling components is highly desirable for researchers involved indeveloping therapies against cancer.Signal TransductionResearch for Cancer Therapy covers advancements in research on the signalingpathways in the human body, especially in some types of cancers, such asbreast cancer, pancreatic cancer and colon cancer.
Key features of this volume include 8 focused topical reviews on signaling pathwaysin a specific cancer type, coverage of multiple cancer types (breast cancer,colon cancer, hepatocellular cancer, multiple myeloma, acute myeloid leukemia,and pancreatic cancer), and coverage of a wide array of signaling pathways (bothreceptor mediated and non receptor mediated pathways). Thisvolume is essential reading for researchers in pharmaceutical R&D andpostgraduate research programs in pharmacology and allied disciplines.Clinicians involved in oncology will also benefit from the information providedin the chapters.
Key features of this volume include 8 focused topical reviews on signaling pathwaysin a specific cancer type, coverage of multiple cancer types (breast cancer,colon cancer, hepatocellular cancer, multiple myeloma, acute myeloid leukemia,and pancreatic cancer), and coverage of a wide array of signaling pathways (bothreceptor mediated and non receptor mediated pathways). Thisvolume is essential reading for researchers in pharmaceutical R&D andpostgraduate research programs in pharmacology and allied disciplines.Clinicians involved in oncology will also benefit from the information providedin the chapters.
Table of Contents
Chapter 1 Wnt Signaling in Breast Cancer Oncogenesis, Development- And Progression
- Norman Fultang and Bela Peethambaran
- Introduction
- Overview
- Wnt Biosynthesis and Regulation
- Types of Pathways
- The Canonical Wnt Signaling Pathway in Breast Cancer
- Non-Canonical Wnt Pathways in Breast Cancer
- Regulators of Wnt Signaling
- Wnt and Breast Cancer Stem Cells
- Role of Wnt Signaling in Breast Cancer Tumorigenesis And
- Progression
- Animal Models and Clinical Significance of Wnt Signaling In
- Breast Cancer
- Wnt Signaling in Triple-Negative Breast Cancer
- Natural Compounds Targeting Wnt Pathways as Cancer
- Therapeutics
- Small Molecules and Novel Therapeutics That Target Wnt
- Signaling
- Conclusion and Future Directions
- Abbreviations
- Consent for Publication
- Conflict of Interest
- Acknowledgements
- References
Chapter 2 Cxcr4 Signaling and Its Impact on Tumor Progression And
- Metastasis in Breast Cancer
- Dayanidhi Raman, Cory M. Howard, Sangita Sridharan and Augustus M.C. Tilley
- Introduction
- Cxcl12-Cxcr4 Axis
- Cxcr4 Pathways Operating in Breast Cancer
- Pi3K Pathway
- Akt (Or Protein Kinase B) Signaling Node
- Mtor Node
- Mapk Pathway
- Oncoprotein Translation by Mapks
- Epithelial-Mesenchymal Transition (Emt) and Cell Migration
- Inactivation of Erk1/2
- C-Src Pathway
- Jak-Stat Pathway
- Cross-Talk of Cxcr4 with Other Receptor and Non-Receptor Tyrosine Kinases and Its
- Interaction with Specific Adaptors
- Stromal Cell Recruitment to the Tme
- Therapeutic Implications
- Conclusion
- Consent for Publication
- Conflict of Interest
- Acknowledgements
- References
Chapter 3 Epidermal Growth Factor Receptor Signaling in Colon
- Cancer
- Avtar S. Meena and Pradeep K. Shukla
- Colorectal Cancer and Risk Factors
- Egfr Signaling in Crc
- Egf-Like Growth Factors
- Mapk Signaling
- Pi3K/ Akt Signaling
- Emerging Role of Egfr in the Development of Colon Cancer
- Egfr Therapies
- Anti-Egfr Receptor Therapy
- Anti-Egfr Monoclonal Antibodies
- Cetuximab
- Panitumumab
- Anti-Egfr Tyrosine Kinase Inhibitors
- Erlotinib
- Gefitinib
- Mechanism of Resistance to Anti-Egfr Therapy
- Low Expression of Amphiregulin, Epiregulin, and Egfr Gene Copy Number
- Egfr Downstream Effectors
- Ras
- Raf
- Pik3Ca
- Pten
- Role of Egfr in Other Disease Models
- Egfr and Probiotics
- Egfr and Inflammation
- Egfr and Glutamine
- Future Direction
- Conclusion
- Consent for Publication
- Conflict of Interest
- Acknowledgements
- References
Chapter 4 Targeting the Pi3K/Akt/Mtor Signaling Pathway In
- Hepatocellular Carcinoma: Current State and Future Trends
- Neelam Yadav and Yoganchal Mishra
- Introduction
- Risk Factors for Hcc
- Pathophysiology
- Basic Signaling Pathways
- Pi3K/Akt/Mtor Signaling Pathway
- Activation of Pi3K/Akt/Mtor Pathway
- Targeting Pi3K/Akt/Mtor Signaling Pathway
- Targeting Pi3K
- Targeting Akt
- Targeting Mtor
- Clinical Perspectives of the Current State
- Challenges in Targeting Pi3K/Akt/Mtor Pathway
- Conclusion and Future Perspective
- Consent for Publication
- Conflict of Interest
- Acknowledgements
- References
Chapter 5 Mapk Signaling Pathway: a Central Target in Pancreatic
- Cancer Therapeutics
- Sahdeo Prasad and Sanjay K. Srivastava
- Introduction
- Activation of the Mapk Pathway
- Conclusion
- Consent for Publication
- Conflict of Interest
- Acknowledgements
- References
Chapter 6 Role of Nf-Κb Activation in Multiple Myeloma and Other
- Hematological Malignancies
- Loukik Arora, Frank Arfuso, Alan Prem Kumar and Gautam Sethi
- Introduction
- Structure and Signaling Cascade of Nf-ĸb Proteins
- Nf-Κb Activation and Signaling
- Canonical or Classical Pathway
- Non-Canonical Pathway
- Inhibition of the Nf-ĸb Pathway
- Role of Nf-ĸb in Solid Tumors and Hematological Malignancies
- Role of Nf-ĸb in Multiple Myeloma
- Nf-ĸb Activation in Leukemia and Lymphoma
- Potential Pharmacological Targeting of Nf-ĸb Pathway
- Receptor Blockers and Upstream Signaling Inhibitors
- Ikk Inhibitors
- Ubiquitination and Proteasome Inhibitors
- Direct Nf-ĸb and Nuclear Activity Inhibitors
- Non-Steroidal Anti-Inflammatory Drugs
- Glucocorticoids and Immunomodulators
- Natural Products
- Conclusion
- List of Abbreviations
- Consent for Publication
- Conflict of Interest
- Acknowledgements
- References
- Mapk Pathway in Pancreatic Cancer Progression
- Role of Mapk Inhibitors in Pancreatic Cancer Therapeutics
- Krishne Gowda, Max Von Suskil, Omar Al-Adat, Jennifer Dang, Kuntal Bhowmick
- Prachi S. Narayan, Shantu G Amin and Manoj K. Pandey
Chapter 8 The Tumor Microenvironment Mediated Signaling Pathways
- In the Progression of Acute Myeloid Leukemia
- Anup S. Pathania, Rachel Weber and Kishore B. Challagundla
- Introduction
- The Tumor Microenvironment and Acute Myeloid Leukemia
- Leukemic Cells and the Modulation of the Tumor
- Microenvironment
- The Tumor Microenvironment and Acute Myeloid Leukemia
- Therapy Response
- Acute Myeloid Leukemia and Exosomes
- E
- The Cmyc and Acute Myeloid Leukemia
- The Exosomes and C-Myc in the Progression of Acute Myeloid
- Leukemia
- Conclusions and Outlook
- Consent for Publication
- Conflict of Interest
- Acknowledgements
- References
- Introduction
- The Btk Signaling Pathway
- Structure and Activation of Btk
- Role of Btk in B Cell Receptor Signaling
- Btk in Other Signaling Pathways
- Chemokine Receptors
- Toll-Like Receptors
- Fc Receptor Signaling
- Role of Btk Signaling in Hematological Malignancies
- Chronic Lymphocytic Leukemia
- Mantle Cell Lymphoma
- Waldenström's Macroglobulinemia
- Diffuse Large B-Cell Lymphoma
- Multiple Myeloma
- The Development of Btk Inhibitors
- Ibrutinib
- Acalabrutinib (Acp-196]
- Bgb-3111
- Tirabrutinib (Ono/Gs-4059]
- Ks99
- Conclusions and Future Directions
- Consent for Publication
- Conflict of Interest
- Acknowledgements
- Abbreviations
- References
- Subject Index
Author
- Manoj K. Pandey
- Vijay P. Kale
